Condie Carmack 
Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk. Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival. Obesity-related cancers include multiple myeloma, … Read more
By AL LEWIS Last month Aon, the major benefits consulting firm, released a “study” claiming: A significant opportunity to reduce healthcare costs for employers and enhance overall workforce health through a comprehensive obesity management program that includes GLP-1 medications. This, of course, is the opposite of what most researchers have shown. And in the immortal … Read more
Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a potential role for dermatologists in obesity management. Medscape Medical News
In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or full dosing was achieved. Medscape Medical News
Abstract Aims GLP-1 and GIP-GLP-1 agonists have emerged as potent weight-loss medications. These incretin mimetics often have low patient adherence, and as with any medication, clinically meaningful efficacy requires adequate adherence. But what constitutes “adequate” adherence for incretin mimetics? The purpose of this paper is to address this question. Materials and Methods We use mathematical … Read more
A new study shows GLP-1 drugs liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers. Carsten Snejbjerg/Bloomberg via Getty Images First-generation GLP-1 weight-loss drugs could help reduce the risk of obesity-related cancers, new research shows. These medications have been around longer than the newer, better-known GLP-1 drugs, such as Ozempic, but they … Read more
Former FDA Commissioner Dr. David Kessler and Dr. Jon LaPook join CBS Mornings to discuss the science behind weight loss drugs and the president’s new plan to lower prescription costs.
Nestlé has announced that it intends to sell Perrier and all its other water brands. Reuters is reporting that the retail giant has commissioned the Rothschild bank to sell off its entire water division, as the company looks to “refocus” on other brands. “Under new CEO Laurent Freixe, Nestlé has been trying to narrow its … Read more
In this podcast, Motley Fool host Dylan Lewis and analysts Tim Beyers and Bill Mann discuss: The Fed’s continued wait-and-see approach to tariff policy, inflation, and interest rate cuts. Ford‘s warning of tariff impacts. Why MercadoLibre is worth a look amid macro uncertainty. How Uber and DoorDash are both flourishing as they cash in on … Read more
In a large data analysis, GLP-1 agonists lowered risk for many diseases that are not related to diabetes.